SCPS (Scopus BioPharma) Research & Development: $5.27 Mil (TTM As of Jun. 2023)


What is Scopus BioPharma Research & Development?

Scopus BioPharma SCPS +50.00% Research & Development is $5.27 Mil as of Jun. 2023.

Research & Development is the aggregate amount of research and development expenses during the year. Scopus BioPharma's Research & Development for the three months ended in Jun. 2023 was $1.99 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $5.27 Mil.

Scopus BioPharma  (OTCPK:SCPS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Scopus BioPharma Research & Development Related Terms

Scopus BioPharma Research & Development Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Research & Development Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial 0.28 0.46 7.42 15.02 2.68

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.92 0.75 1.61 1.99

Scopus BioPharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $5.27 Mil mean?
Scopus BioPharma (SCPS) has a Research & Development of $5.27 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's Research & Development too high?
Scopus BioPharma's current Research & Development is $5.27 Mil.
How does Scopus BioPharma's Research & Development compare to AMPE and DRMA?
Scopus BioPharma's Research & Development of $5.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current Research & Development is $5.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Research & Development of $5.27 Mil. The current Research & Development is $5.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Research & Development is $5.27 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.